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Abstract
Tetrahydrocurcumin (THC) is the principal metabolite of curcumin and has antioxi-
dant properties. In the present investigation, the effect of THC on renal and cardio-
vascular outcomes was studied in rats with chronic kidney disease (CKD). CKD rats
were randomized following 5/6 nephrectomy to a special diet for 9 weeks which
contained 1% THC (CKD+THC group). Low-dose polyenylphosphatidylcholine was
used as a lipid carrier to increase bioavailability. Endpoints included tail blood pres-
sure, normalized heart weight, plasma and urine biochemical data, and kidney tissue
analyses. CKD animals demonstrated increased proteinuria, decreased creatinine
clearance, hypertension, and cardiac hypertrophy. The antioxidant proteins CuZn
SOD and glutathione peroxidase were decreased in the remnant kidney, while apop-
tosis (caspase-3) and fibrosis (alpha-SM actin) were increased. Renal fibrosis was
confirmed histologically on trichrome staining. These pathologic changes were ame-
liorated in the CKD+THC group with significant decrease in proteinuria, hyperten-
sion, and kidney fibrosis. THC therapy restored levels of CuZn SOD and glutathione
peroxidase. Consistent with prior reports, dietary THC did not improve nuclear Nrf2
levels. In summary, dietary THC therapy improved expression of antioxidant pro-
teins in the remnant kidney, decreased renal fibrosis and proteinuria, and amelio-
rated hypertension in 5/6 nephrectomized rats.
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1 | INTRODUCTION
The pathogenesis of chronic kidney disease (CKD) involves a com-
plex interaction of inflammation, oxidative stress, and fibrosis that
lead to progressive glomerular and tubulointerstitial scarring.1,2
Oxidative stress promotes inflammation via toxic effects of reactive
oxygen species (ROS) and by activation of redox-sensitive proinflam-
matory signaling pathways. Besides driving kidney failure, inflamma-
tion and oxidative stress perpetuate atherosclerosis and vascular
calcification, thus directly contributing to the elevated cardiovascular
morbidity and mortality rates in CKD patients.2,3
Abbreviations: BP, blood pressure; BUN, blood urea nitrogen; CKD, chronic kidney
disease; CrCl, creatinine clearance; CRP, C-reactive protein; PPC,
polyenylphosphatidylcholine; ROS, reactive oxygen species; THC, tetrahydrocurcumin.
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Curcumin (diferuloylmethane; 1,7-bis[4-hydroxy-3-methoxyphenyl]-
1,6-heptadiene-3,5-dione) is the major bioactive component of the herb
turmeric or Curcuma longa L., a widely used natural food product in curry
powder and food coloring (mustard). The principal metabolite of cur-
cumin is tetrahydrocurcumin (THC), produced by medium-chain dehy-
drogenase/reductase metabolism of enteric bacteria.4 Curcumin has
been studied in a variety of settings including cancer, inflammatory
bowel disease, neurogenesis, and diabetes mellitus.5-9 While it has
strong anti-inflammatory and antioxidant properties, curcumin has been
shown to exert some prooxidant activity when tested in tumor cell
lines.10 THC has been reported to exhibit similar antioxidant properties
11 without the unfavorable prooxidant effects, and may be superior in
the induction of glutathione peroxidase and quenching of free radicals.12
Beneficial antioxidative effects of THC have been reported in
acute kidney injury models. THC prevented ferric nitrilotriacetate and
chloroquine-induced oxidative kidney injury via inhibition of lipid per-
oxidation and upregulation of antioxidant catalytic activity.12,13 In rats
with streptozotocin-induced diabetes mellitus, THC has been shown
to decrease tissue oxidative stress, decrease albuminuria and serum
creatinine, and improve plasma insulin levels.14-16 Curcumin but not
THC has previously been investigated in 5/6 nephrectomized CKD
rats 17-19 and we chose to study THC in this nephron mass reduction
model to determine effects on proteinuria, fibrosis, and inflammation.
THC is more stable than curcumin, with a degradation half-life in
cell culture medium of 813 minutes as compared to 186 minutes for
curcumin.20 While THC has better enteric absorption than curcumin,
both molecules are poorly water-soluble; thus, bioavailability is a
major issue.21 Delivery of curcumin with a lipid carrier such as
polyenylphosphatidylcholine (PPC) has been shown to increase
plasma levels fivefold in rats.22
Our current project investigated effects of dietary 1% tetrahy-
drocurcumin in the well-established rat 5/6 nephrectomy model. A
low concentration of PPC was added to enhance curcuminoids
bioavailability. We report that THC with PPC had positive renal
effects, which correlated with decreased systemic hypertension and
less cardiac hypertrophy.
2 | MATERIALS AND METHODS
2.1 | Experimental animals
Female Sprague-Dawley rats (body weight 225-250 g, Charles River,
Wilmington, MA) were randomized to CKD and control groups. The
experimental groups were: control (CTL, n = 6), CKD (n = 9), and CKD
treated with THC diet (CKD+THC, n = 10). Female rats were chosen as
they develop more proteinuria and renal fibrosis when subjected to 5/6
nephrectomy, as compared to male rats.23 The CKD group underwent
5/6 nephrectomy: resection of the 2 poles of the left kidney followed
by right total nephrectomy 1 week later. Surgeries were done under
inhaled isoflurane anesthesia and rats were given buprenorphine
0.05 mg/kg i.p. at the start of surgery for analgesia. CKD rats were ran-
domized 10 days after right nephrectomy to regular chow or special
diet 9 9 weeks. Tail blood pressure (BP) measurements and 24 hours
urine collections (within individual metabolic cages, 6 animals per group)
were done within 1 week prior to study termination. All experimental
protocols were approved by the University of California, Irvine Institu-
tional Committee for the Use and Care of Experimental Animals. The
experimental timeline is shown in Figure 1.
2.2 | Tetrahydrocurcumin Diet
We chose a 1% THC diet based on review of the literature that showed
measurable physiologic effects with 0.5%-4% dietary curcumin.24-28
Diets were based on the 2020X regular rodent chow (Teklad Diets,
Madison WI). Additional diet components were tetrahydrocurcumin
(curcumin C3 reduct with tetrahydrocurcuminoids 95%, Sabinsa Corpo-
ration, Payson UT) and polyenylphosphatidylcholine (PPC, PhosChol
Liquid Concentrate whereby 1 teaspoon contains 3000 mg of purified
PPC, Nutrasal, Inc., Scottsdale AZ). The 1% THC diet was manufactured
into pellet form by Teklad Diets: diet formulation TD.140853 contained
1% tetrahydrocurcumin + PPC 3 g/1000 kcal or 9.3 g/kg of diet. PPC
added to the diet served as a lipid carrier to increase bioavailability of
the curcumin compounds22 and the dose 3 g/1000 kcal is well-toler-
ated in rats.29,30 This dose is approximately 100-fold lower than doses
reported to have renoprotective effects.31,32
2.3 | Tissue harvest
Rats were euthanized after 9 weeks on diet by exsanguination using
cardiac puncture under general anesthesia. Kidney and heart tissues
were harvested and processed for western blot analysis and
histology. Plasma was aliquoted for biochemical analysis and mass
spectrophotometry assays.
2.4 | Blood and urine biochemical data
Hemoglobin was measured using an automated meter (Germaine
Labs AimStrip Hemoglobin Test System, catalog# 23-111-280, Fisher
F IGURE 1 Experimental timeline. Study
groups examining dietary
tetrahydrocurcumin (THC) therapy in CKD
rats
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Scientific). Plasma samples were analyzed for blood urea nitrogen
(BUN) and creatinine using colorimetric kits from BioAssay Systems
(Hayward CA). Urine samples were diluted 30x for creatinine (BioAs-
say Systems) and 5x for protein measurements (Rat Urinary Protein
Assay Kit, Chondrex, Inc., Redmond WA). Creatinine clearance nor-
malized to body weight (CrCl, mL/min*kg) was calculated from
24 hours urine collections using the formula: [urine Cr x urine vol-
ume]/[serum Cr x 1440 x body weight]. Plasma C-reactive protein
(CRP) and galectin-3 were measured using rat ELISA kits from
Sigma-Aldrich (St. Louis MO) and MyBioSource (San Diego CA).
2.5 | Mass spectrometry for tetrahydrocurcumin
Analysis was done at the Mass Spectrometry facility at University of
California, Irvine’s Chemistry department. We used a modified proto-
col based on previously described methods.33,34 A 0.1 mL aliquot of
plasma was treated with 100 lL of a solution containing 1000 U of
beta-glucuronidase/sulfatase (EC 3.2.1.31) from Helix pomatia (cata-
log# G7017-1ML, Sigma-Aldrich) in 0.1 mol/L phosphate buffer. The
mixture was vortexed and incubated at 37°C for 1 hour to hydrolyze
the phase-2 conjugates of curcuminoids. After incubation, curcumi-
noids were extracted with 1 mL of ethyl acetate and the mixture
was vortexed for 1 minute, followed by sonication in a water bath
for 15 minutes. The mixture was subjected to centrifugation at
15,000 g for 6 minutes and the upper organic layer was transferred
to a 2 mL microcentrifuge tube and evaporated to dryness at 30°C
in a Speed Vac. This extraction process was repeated, for a total of
2 extractions, yielding 1 dried extract which was reconstituted in
100 lL of 50% acetonitrile solution with 0.1% formic acid. The tube
was sonicated in a water bath for 30 minutes to ensure dissolution.
Tetrahydrocurcumin reference standard fluka 50202-10MG was
purchased from Sigma-Aldrich. A stock 20 mg/mL solution was pre-
pared with acetonitrile and dilutions were prepared with deionized
water to generate a standard curve ranging 0.25-1000 lg/mL. Stan-
dards and prepared samples were injected (10 lL) into the HPLC-
MS/MS instrument, Waters Quattro Premier XE equipped with
UPLC. The UPLC has a BEH C18 column which allows rapid sample
throughput. Mobile phase A was 2% acetonitrile with 0.2% acetic
acid, and mobile phase B was 100% acetonitrile with 0.2% acetic
acid. Analysis was performed using multiple reaction monitoring MS/
MS with standard calibration. The tetrahydrocurcumin transition was
m/z 373.0 ? 136.8.
2.6 | Western blot analysis
Tissue lysates were prepared from kidney samples using Tissue Extrac-
tion Reagent I (Thermo Fisher Scientific, Waltham MA) supplemented
with cOmplete Protease Inhibitor Cocktail (Roche Diagnostics Corp.,
Indianapolis IN). Protein concentration in the tissue homogenates was
determined by bovine serum albumin assay kit (Pierce, Rockford IL)
and 50 lg of total protein per sample was fractionated on 4%-12%
Bis-Tris gradient gel (Invitrogen, Carlsbad CA) then transferred to a
polyvinylidene fluoride membrane. The membrane was blocked with
5% nonfat dry milk solution in Tris-buffered saline with 0.05% Tween,
then incubated with the following primary antibodies: Cu/Zn SOD (fi-
nal concentration 33.5 lg/mL, catalog# 574597 from Calbiochem/
EMD Millipore, Billerica MA), alpha-smooth muscle actin (1:200 dilu-
tion, A5228 from Sigma-Aldrich), iNOS (16 lg/mL, PA1-036 from
Thermo Scientific), glutathione peroxidase-1 (1:200 dilution, AF3798
from R&D Systems, Minneapolis, MN), COX-2 (1:200 dilution,
ab15191 from Abcam), caspase-3 (1:250 dilution, ab90437 from
Abcam), catalase (4 lg/mL, C0979 from Sigma-Aldrich). Beta-actin
antibody (Sigma-Aldrich) at 1:10 000 or GAPDH (Abcam) at 1:20 000
was used to standardize the data. Nuclear lysates were prepared using
the NE-PER kit from Thermo Scientific and probed for Nrf2 (1 lg/mL,
SAB4501984, Sigma) with histone H3 (1:5000 dilution, ab1791,
Abcam) for standardization. The appropriate horseradish peroxidase-
conjugated secondary antibodies (Sigma-Aldrich) were used at
1:20 000 dilution. The membrane was visualized with SuperSignal
West Pico (Pierce) and developed by autoluminography. Band densi-
ties were quantified using ImageJ software (version 10.2) from the
National Institutes of Health (www.imagej.nih.gov/ij/).
2.7 | Histopathological analysis
Paraffin sections of kidney and heart tissue were deparaffinized with
xylene, dehydrated in alcohol series, stained with hematoxylin and
eosin (H&E) or Masson’s trichrome, and examined under a photomi-
croscope (Nikon Eclipse, Japan). An ImageJ macro was used for quan-
tification of kidney fibrosis (% area stained blue on Masson’s
trichrome) while maintaining the same threshold settings across all
slides to avoid bias.35 Three images of kidney cortex were captured at
10X objective from 6 animals per group by a researcher blinded to the
study groups (RGT), and mean % area was calculated per animal.
2.8 | Statistical analysis
Data were screened for outliers using the Grubbs’ test (extreme stu-
dentized deviate method, http://graphpad.com/quickcalcs/grubbs1/).
Bartlett’s test was used to assess homogeneity of variances across
groups. For datasets with equal variances, group data were analyzed
using one-way ANOVA with post hoc Tukey, and P < .05 was con-
sidered significant. For nonparametric data, Kruskal-Wallis analysis
was used (P < .05 considered significant) with Dunn’s Multiple Com-
parison Test. Data are reported as mean  SD for plasma and urine
biochemical data and weights, and mean  SEM for western blot,
histologic and mass spectrometry quantitation. Figures were gener-
ated using GraphPad Prism 4 software (GraphPad Software, San
Diego CA).
3 | RESULTS
3.1 | General Data
At study conclusion, there were 6 rats in the normal control group
(CTL), 6 rats in the nontreated CKD group, and 9 rats in the 1%
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tetrahydrocurcumin/PPC group (CKD+THC). There were 3 deaths in
the nontreated CKD group and 1 death in the CKD+THC group dur-
ing the 9 weeks on assigned diet. Our study was not powered to
detect mortality differences. Table 1 and Figure 2 summarize plasma
and urine biochemical data, body weights, heart weights, and tail
blood pressure values. BUN at week 0 and week 9 of assigned diet
and plasma creatinine were significantly elevated in the CKD groups
compared to CTL, while creatinine clearance (CrCl) was significantly
decreased. Body weight, hemoglobin, plasma CRP, and galectin-3
were not significantly different between groups, although average
CRP was highest in the nontreated CKD group. There was a trend
for improved BUN, creatinine, and CrCl in the THC treatment
groups, although this did not reach statistical significance.
Tail systolic and diastolic BP readings were significantly elevated
in 5/6 nephrectomized rats and this hypertension was ameliorated in
CKD rats on THC diet (Figure 2). The CKD+THC rats also had a sig-
nificant decrease in proteinuria by ~50% compared to CKD animals
(47.6  13.8 vs 88.5  30.9 mg protein per g creatinine). Further-
more, cardiac hypertrophy (assessed by heart weight normalized to
body weight) was decreased by THC therapy such that normalized
heart weight was not significantly different in this group vs CTL ani-
mals.
3.2 | Mass Spectrometry Analysis
THC was not detected in the plasma from CTL and nontreated CKD
rats. Average plasma THC level was 24.0  3.3 lg/mL (0.06 mmol/
L) in CKD+THC rats.
3.3 | Kidney western blot data
Western blot analysis of markers of oxidative stress, apoptosis, and
fibrosis in kidney lysates is summarized in Figure 3. The antioxidant
(scavenging) enzymes metalloenzyme copper-zinc superoxide
TABLE 1 Body weights, normalized heart weights, and blood and
urine biochemical data for the 4 experimental groups. Data are







Body weight (g) 282  18 260  13 257  11
Heart weight/body
weight (g/kg) a
3.5  0.3 4.6  0.5# 4.3  0.8
Hemoglobin (g/dL) 14.1  0.5 13.7  1.1 12.3  1.5
BUN at start of special
diet (mg/dL)
N/A 63  10 69  15
Terminal BUN (mg/dL) a 20.6  3.4 87.1  32.9# 61.3  25.5#
Plasma creatinine
(mg/dL) a
0.4  0.1 1.4  0.5# 1.1  0.2#
CrCl (mL/min*kg) 5.2  1.2 1.8  1.1# 2.8  0.7#
24 h total urine
protein (mg) a
18  17 663  252# 528  119
Plasma C-reactive
protein (mg/mL)
1.9  1.1 2.8  1.2 2.7  0.9
Plasma galectin-3
(ng/mL)
444  148 475  162 400  208
BUN, blood urea nitrogen; CrCl, creatinine clearance; CKD, chronic kid-
ney disease; CTL, controls; THC, tetrahydrocurcumin/PPC diet.
aData with unequal variances by Bartlett’s test, analyzed using Kruskal-
Wallis test.
#P < .05 vs CTL.
F IGURE 2 Blood pressure and
proteinuria were decreased with
tetrahydrocurcumin (THC) therapy. Systolic
blood pressure (A) and diastolic blood
pressure (B) were increased in CKD rats,
and decreased with THC therapy.
Proteinuria as assessed by urine protein/
creatinine ratio (C) was significantly
elevated in 5/6 nephrectomized CKD
animals, and was significantly decreased
with THC therapy. Data shown as
mean  SEM. #P < .05 vs CTL; *P < .05 vs
CKD
4 of 8 | LAU ET AL.
dismutase (CuZn SOD) and glutathione peroxidase (GPX-1) were
suppressed in the remnant kidney from CKD animals. Levels were
restored with dietary THC treatment. Another cytoplasmic antioxi-
dant enzyme, catalase, was similarly suppressed in CKD and there
was a trend for improved levels with THC diet (P = .24 across
groups, data not shown). Inducible nitric oxide synthase (iNOS) was
increased in CKD and there was a trend for decreased levels with
THC diet (P = .09); COX-2 levels were not different across CKD
groups (data not shown). Consistent with prior work that has shown
THC to be a weak inducer of Nrf2 translocation compared to its par-
ent compound curcumin,36 nuclear Nrf2 levels were not increased
with THC treatment (data not shown). Apoptosis and fibrosis were
F IGURE 3 Improvement in markers of
oxidative stress on western blot and
histology. Western blots depicting protein
abundance of oxidative stress,
inflammation, and fibrosis mediators in
kidney lysates from the 3 experimental
groups. The antioxidant (scavenging)
proteins (A) copper-zinc superoxide
dismutase (CuZn SOD), and (B) glutathione
peroxidase (GPX-1) were decreased in
CKD and levels were restored with dietary
THC therapy. The apoptosis marker (C)
caspase-3 and the fibrosis marker (D)
alpha-smooth muscle actin (alphaSM-actin)
were increased in the remnant kidney from
CKD rats and were decreased with THC
therapy. (E) Representative micrographs of
kidney tissue from the 3 experimental
groups, stained with Masson’s trichrome to
assess degree of fibrosis (percent area
stained blue, 10X objective). Area stained
blue was doubled in CKD vs CTL animals.
This area was decreased ~20% with THC
therapy. Data shown as mean  SEM.
#P < .05 vs CTL; *P < .05 vs CKD
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increased in the remnant kidney from CKD rats as indicated by ele-
vated caspase-3 and alpha-smooth muscle actin (alphaSM-actin), and
these markers were decreased with THC diet.
3.4 | Histology results
Masson’s trichrome was used to visually assess percent area affected
by fibrosis (stained blue) in kidney tissues. Three cortical micrographs
per kidney section were assessed using an ImageJ macro and an
average was calculated per animal; 6 animals were assessed per
experimental group. Percent area stained blue was doubled in the
CKD animals compared to CTL rats (63.9% vs 31.7%) and was
decreased ~20% with THC treatment (51.9%). Representative kidney
sections and group data are shown in Figure 3E. No increase in
fibrosis was observed in the heart tissue from the CKD groups, com-
pared to CTL rats (data not shown).
4 | DISCUSSION
To the best of our knowledge, this is the first study of dietary
tetrahydrocurcumin in 5/6 nephrectomy rats. THC treatment had
beneficial renal and cardiac effects. CKD animals exhibited hyperten-
sion, proteinuria, renal fibrosis, and cardiac hypertrophy; dietary THC
improved all of these parameters. Chronic oxidative stress and
inflammation are hallmarks of CKD37,38; in this study, levels of
antioxidant enzymes CuZn SOD and GPX were decreased, while
inflammatory iNOS and the apoptosis mediator caspase-3 were
increased in the remnant kidney tissues from CKD rats. These
derangements were corrected with 1% THC diet. The proposed
pathways by which THC improves oxidative stress and decreases
apoptosis and fibrosis are summarized in Figure 4.
CKD is a state of SOD deficiency whereby the latter promotes
blood pressure dysregulation and nitric oxide metabolism.39 The
observed renoprotective effects in our study are consistent with
reports from other rodent models whereby THC enhanced antioxida-
tive activity of superoxide dismutase, catalase and glutathione perox-
idase.12,13,16 The net effect is decreased production of reactive
oxygen species, with subsequent downregulation of the caspase-3
apoptosis pathway40 and tissue fibrosis. THC has similarly been
shown to decrease albuminuria and blunt rise in serum creatinine in
rats with diabetic nephropathy.14-16
The cardioprotective outcomes (normalized blood pressure,
decreased cardiac hypertrophy) were likely secondary to decreased
severity of CKD, but may have also reflected direct myocardial
benefits of THC in terms of suppressing ROS production, apopto-
sis, and fibrosis. Curcumin therapy has been associated with
decreased cardiac oxidative stress and improved ejection fraction
in models of CKD, obesity, and cardiac ischemia/reperfusion.41-43
We further examined circulating galectin-3 levels given the strong
evidence that this beta-galactoside-binding lectin promotes tissue
fibrosis.44,45 We found no differences in galectin-3 levels between
the experimental rat groups, suggesting that galectin-3 was not a
significant instigator of renal fibrosis and is not a useful biomarker
in this CKD model.
The decrease in proteinuria with THC therapy is noteworthy
as increased proteinuria promotes fibrosis and more rapid loss of
kidney function in CKD patients46,47 and associates with higher
F IGURE 4 Summary of pathways by which tetrahydrocurcumin (THC) decreases oxidative stress and renal fibrosis. There is heightened
oxidative stress in CKD and transfer of electrons by mitochondrial, peroxisomes, nicotinamide adenine dinucleotide phosphate (NADPH), and
nitric oxide synthase (NOS, inducible iNOS and endothelial eNOS) reduction pathways results in generation of damaging reactive oxygen
species (ROS) including superoxide, nitric oxide, peroxynitrite, and hydroxyl ions. This oxidative stress promotes inflammation, cell death, and
fibrosis. THC restores expression of antioxidant (scavenging) proteins including superoxide dismutase (SOD), catalase, and glutathione
peroxidase (GPX) to decrease levels of ROS, thus decreasing downstream fibrosis
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cardiovascular mortality.48 Anti-proteinuric interventions are lacking
in clinical practice, other than pharmacologic blockade of the
renin-angiotensin-aldosterone system.49,50 Concurrent with
decreased proteinuria, we noted a trend for improved kidney func-
tion as evidenced by lower BUN and plasma creatinine, and higher
creatinine clearance in the THC-treated animals. We postulate that
this effect may have reached statistical significance if the THC
diet had been started immediately after the second surgery
(Figure 1). Other groups have reported that THC significantly
decreased serum creatinine in nonsurgical kidney injury models, for
example, when given at the time of chloroquine-induced oxidative
stress.12,13
The use of PPC as a lipid carrier increased intestinal uptake of
curcuminoids and yielded robust THC plasma levels, averaging
0.06 mmol/L in the CKD+THC treatment group. Aside from boosting
enteric absorption of curcuminoids, PPC has been reported to have
beneficial cytoprotective effects in the liver and kidney.30-32 Of note,
prior studies used much higher doses of oral PPC (100 mg/kg body
weight),31,32 whereas our present study used a concentration of
9.3 g/kg of diet which has been shown to have protective effects
against alcohol-induced liver oxidative injury.29,30 Assuming that a
250 g adult rat eats ~25 g of chow per day, this approximates a
PPC dose of 0.2 g/day or 0.93 mg/kg body weight ,that is, 100-fold
lower than the reported renoprotective dose.31,32
Future studies will need to examine effects of altered gut per-
meability on THC bioavailability. Altered intestinal microbiome in
CKD induces gut inflammation and degradation of epithelial tight
junctions leading to a “leaky” barrier, with subsequent translocation
of luminal toxins into the bloodstream.51 In prior CKD rat studies,
uremia was associated with increased gut permeability to poly-
ethylene glycols ranging up to 1162 Da in size.52 THC has a
molecular weight of 372.4 Da and thus theoretically could be sub-
ject to increased gut translocation in CKD. However, curcuminoids
have been reported to decrease intestinal barrier dysfunction in
cell culture models53 and this could negate any increase in THC
uptake. Further in vivo studies are needed to clarify the net drug
bioavailability.
In summary, 1% tetrahydrocurcumin with PPC diet improved
expression of antioxidant enzymes in the remnant kidney, decreased
renal apoptosis and fibrosis, and ameliorated proteinuria, hyperten-
sion, and cardiac hypertrophy in 5/6 nephrectomized rats. Further
studies are needed to investigate whether these beneficial effects of
THC therapy can be replicated in patients with CKD.
ACKNOWLEDGEMENTS
The study was funded by an unrestricted research grant from Hub




Wei Ling Lau http://orcid.org/0000-0002-3118-1073
REFERENCES
1. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and
progression of chronic renal failure. Semin Nephrol. 2004;24:354-
365.
2. Cachofeiro V, Goicochea M, deVinuesa SG, Oubi~na P, Lahera V,
Lu~no J. Oxidative stress and inflammation, a link between chronic
kidney disease and cardiovascular disease. Kidney Int Suppl 2008;
111:S4-S9.
3. Massy ZA, Maziere C, Kamel S, et al. Impact of inflammation and
oxidative stress on vascular calcifications in chronic kidney disease.
Pediatr Nephrol. 2005;20:380-382.
4. Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M. Dis-
covery of the curcumin metabolic pathway involving a unique
enzyme in an intestinal microorganism. Proc Natl Acad Sci USA.
2011;108:6615-6620.
5. Wu JC, Tsai ML, Lai CS, Wang YJ, Ho CT, Pan MH. Chemopreventa-
tive effects of tetrahydrocurcumin on human diseases. Food Funct.
2014;5:12-17.
6. Dong S, Zeng Q, Mitchell ES, et al. Curcumin enhances neurogenesis
and cognition in aged rats: implications for transcriptional interac-
tions related to growth and synaptic plasticity. PLoS ONE. 2012;7:
e31211.
7. Meng B, Li J, Cao H. Antioxidant and antiinflammatory activities of
curcumin on diabetes mellitus and its complications. Curr Pharm Des.
2013;19:2101-2113.
8. Vecchi Brumatti L, Marcuzzi A, Tricarico PM, Zanin V, Girardelli M,
Bianco AM. Curcumin and inflammatory bowel disease: potential and
limits of innovative treatments. Molecules. 2014;19:21127-21153.
9. Das L, Vinayak M. Long term effect of curcumin in restoration of
tumour suppressor p53 and phase-II antioxidant enzymes via activa-
tion of Nrf2 signalling and modulation of inflammation in prevention
of cancer. PLoS ONE. 2015;10:e0124000.
10. Aggarwal BB, Deb L, Prasad S. Curcumin differs from tetrahydrocur-
cumin for molecular targets, signaling pathways and cellular
responses. Molecules. 2015;20:185-205.
11. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the beta-dike-
tone moiety in the antioxidative mechanism of tetrahydrocurcumin.
Biochem Pharmacol. 1996;52:519-525.
12. Okada K, Wangpoengtrakul C, Tanaka T, Toyokuni S, Uchida K,
Osawa T. Curcumin and especially tetrahydrocurcumin ameliorate
oxidative stress-induced renal injury in mice. J Nutr. 2001;131:2090-
2095.
13. Pari L, Murugan P. Tetrahydrocurcumin: effect on chloroquine-
mediated oxidative damage in rat kidney. Basic Clin Pharmacol Toxi-
col. 2006;99:329-334.
14. Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose,
plasma insulin and hepatic key enzymes in streptozotocin induced
diabetic rats. J Basic Clin Physiol Pharmacol. 2005;16:257-274.
15. Murugan P, Pari L. Antioxidant effect of tetrahydrocurcumin in
streptozotocin-nicotinamide induced diabetic rats. Life Sci.
2006;79:1720-1728.
16. Murugan P, Pari L. Influence of tetrahydrocurcumin on hepatic and
renal functional markers and protein levels in experimental type 2
diabetic rats. Basic Clin Pharmacol Toxicol. 2007;101:241-245.
17. Tapia E, Zatarain-Barron ZL, Hernandez-Pando R, et al. Curcumin
reverses glomerular hemodynamic alterations and oxidant stress in
5/6 nephrectomized rats. Phytomedicine. 2013;20:359-366.
LAU ET AL. | 7 of 8
18. Soetikno V, Sari FR, Lakshmanan AP, et al. Curcumin alleviates
oxidative stress, inflammation, and renal fibrosis in remnant kidney
through the Nrf2-keap1 pathway. Mol Nutr Food Res. 2013;57:1649-
1659.
19. Ghosh SS, Krieg R, Massey HD, et al. Curcumin and enalapril amelio-
rate renal failure by antagonizing inflammation in 5/6 nephrec-
tomized rats: role of phospholipase and cyclooxygenase. Am J
Physiol Renal Physiol. 2012;302:F439-F454.
20. Vijaya Saradhi UV, Ling Y, Wang J, et al. A liquid chromatography-
tandem mass spectrometric method for quantification of curcumi-
noids in cell medium and mouse plasma. J Chromatogr B Analyt Tech-
nol Biomed Life Sci. 2010;878:3045-3051.
21. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailabil-
ity of curcumin: problems and promises.Mol Pharm. 2007;4:807-818.
22. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP,
Gescher AJ. Comparison of systemic availability of curcumin with
that of curcumin formulated with phosphatidylcholine. Cancer Che-
mother Pharmacol. 2007;60:171-177.
23. Fleck C, Appenroth D, Jonas P, et al. Suitability of 5/6 nephrectomy
(5/6NX) for the induction of interstitial renal fibrosis in rats–influ-
ence of sex, strain, and surgical procedure. Exp Toxicol Pathol.
2006;57:195-205.
24. Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH.
Inhibitory effects of dietary curcumin on forestomach, duodenal, and
colon carcinogenesis in mice. Cancer Res. 1994;54:5841-5847.
25. Inano H, Onoda M, Inafuku N, et al. Potent preventive action of cur-
cumin on radiation-induced initiation of mammary tumorigenesis in
rats. Carcinogenesis. 2000;21:1835-1841.
26. Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of dietary cur-
cumin on glutathione S-transferase and malondialdehyde-DNA
adducts in rat liver and colon mucosa: relationship with drug levels.
Clin Cancer Res. 2001;7:1452-1458.
27. Chougala MB, Bhaskar JJ, Rajan MG, Salimath PV. Effect of cur-
cumin and quercetin on lysosomal enzyme activities in streptozo-
tocin-induced diabetic rats. Clin Nutr. 2012;31:749-755.
28. Kim SJ, Hellerstein MK. Pharmacological doses of dietary curcumin
increase colon epithelial cell proliferation in vivo in rats. Phytother
Res. 2007;21:995-998.
29. Aleynik MK, Leo MA, Aleynik SI, Lieber CS. Polyenylphosphatidyl-
choline opposes the increase of cytochrome P-4502E1 by ethanol
and corrects its iron-induced decrease. Alcohol Clin Exp Res.
1999;23:96-100.
30. Aleynik SI, Lieber CS. Polyenylphosphatidylcholine corrects the alco-
hol-induced hepatic oxidative stress by restoring s-adenosylmethio-
nine. Alcohol Alcohol. 2003;38:208-212.
31. Demirbilek S, Karaman A, Baykarabulut A, et al. Polyenylphos-
phatidylcholine pretreatment ameliorates ischemic acute renal injury
in rats. Int J Urol. 2006;13:747-753.
32. Akin M, Demirbilek S, Ay S, et al. Attenuation of ureteral obstruc-
tion-induced renal injury by polyenylphosphatidylcholine. Int J Urol.
2007;14:350-356.
33. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a
standardized curcuminoid mixture and its lecithin formulation. J Nat
Prod. 2011;74:664-669.
34. J€ager R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM.
Comparative absorption of curcumin formulations. Nutr J.
2014;13:11.
35. Kennedy DJ, Vetteth S, Periyasamy SM, et al. Central role for the
cardiotonic steroid marinobufagenin in the pathogenesis of experi-
mental uremic cardiomyopathy. Hypertension. 2006;47:488-495.
36. Jeong SO, Oh GS, Ha HY, et al. Dimethoxycurcumin, a Synthetic
Curcumin Analogue, Induces Heme Oxygenase-1 Expression through
Nrf2 Activation in RAW264.7 Macrophages. J Clin Biochem Nutr.
2009;44:79-84.
37. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to
oxidative stress and inflammation in chronic renal failure. Am J Phys-
iol Renal Physiol. 2010;298:F662-F671.
38. Aminzadeh MA, Nicholas SB, Norris KC, Vaziri ND. Role of impaired
Nrf2 activation in the pathogenesis of oxidative stress and inflamma-
tion in chronic tubulo-interstitial nephropathy. Nephrol Dial Trans-
plant. 2013;28:2038-2045.
39. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative
stress and dysregulation of superoxide dismutase and NADPH oxi-
dase in renal insufficiency. Kidney Int. 2003;63:179-185.
40. Song KI, Park JY, Lee S, et al. Protective effect of tetrahydrocur-
cumin against cisplatin-induced renal damage: in vitro and in vivo
studies. Planta Med. 2015;81:286-291.
41. Chen J, Wanming D, Zhang D, Liu Q, Kang J. Water-soluble antioxi-
dants improve the antioxidant and anticancer activity of low concen-
trations of curcumin in human leukemia cells. Pharmazie.
2005;60:57-61.
42. Kuo JJ, Chang HH, Tsai TH, Lee TY. Positive effect of curcumin on
inflammation and mitochondrial dysfunction in obese mice with liver
steatosis. Int J Mol Med. 2012;30:673-679.
43. Hernandez-Resendiz S, Correa F, Garcıa-Ni~no WR, et al. Cardiopro-
tection by curcumin post-treatment in rats with established chronic
kidney disease. Cardiovasc Drugs Ther. 2015;29:111-120.
44. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks acti-
vated macrophages in failure-prone hypertrophied hearts and con-
tributes to cardiac dysfunction. Circulation. 2004;110:3121-3128.
45. Liu YH, D’Ambrosio M, Liao TD, et al. N-acetyl-seryl-aspartyl-lysyl-
proline prevents cardiac remodeling and dysfunction induced by
galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J
Physiol Heart Circ Physiol. 2009;296:H404-H412.
46. Fogo AB. Mechanisms of progression of chronic kidney disease.
Pediatr Nephrol. 2007;22:2011-2022.
47. Staples A, Wong C. Risk factors for progression of chronic kidney
disease. Curr Opin Pediatr. 2010;22:161-169.
48. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion
predicts cardiovascular and noncardiovascular mortality in general
population. Circulation. 2002;106:1777-1782.
49. Praga M. Therapeutic measures in proteinuric nephropathy. Kidney
Int Suppl 2005;99:S137-S141.
50. Kalaitzidis RG, Bakris GL. The current state of RAAS blockade in the
treatment of hypertension and proteinuria. Curr Cardiol Rep.
2009;11:436-442.
51. Lau WL, Kalantar-Zadeh K, Vaziri ND. The gut as a source of inflam-
mation in chronic kidney disease. Nephron. 2015;130:92-98.
52. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Increased
intestinal permeability to differently sized polyethylene glycols in
uremic rats: effects of low- and high-protein diets. Nephron.
1990;56:306-311.
53. Wang J, Ghosh SS, Ghosh S. Curcumin improves intestinal barrier
function: modulation of intracellular signaling, and organization of
tight junctions. Am J Physiol Cell Physiol. 2017;312:C438-C445.
How to cite this article: Lau WL, Khazaeli M, Savoj J, et al.
Dietary tetrahydrocurcumin reduces renal fibrosis and cardiac
hypertrophy in 5/6 nephrectomized rats. Pharmacol Res
Perspect. 2018;e00385. https://doi.org/10.1002/prp2.385
8 of 8 | LAU ET AL.
